NanoViricides extends CEO/CFO contracts; raises CEO line of credit to $3M through 2027

NANOVIRICIDES, INC.

President/CEO Diwan term extended to June 30, 2026; base salary $400,000/yr; granted 10,204 Series A preferred shares vesting quarterly.
CFO Vyas term extended to June 30, 2026; compensation $10,800/month; health insurance reimbursement up to $2,500/month.
CEO Diwan's line of credit increased from $2M to $3M; maturity extended to March 31, 2027; 12% interest; secured by company property.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.